In case of CKD, the use of a GLP-1RA with proven cardiovascular benefit is only recommended in those who have not achieved individualized glycemic targets despite SGLT2i treatment, or in whom SGLT2is are contraindicated or not tolerated [6, 8]
It helps in the formation of new blood vessels (angiogenesis), ensuring that the bone injury receives adequate circulation for faster healing
The Medicare GLP-1 Bridge is a CMS (Centers for Medicare and Medicaid Services) demonstration program announced in early 2026
When looking at weight loss thresholds, 78% of patients on tirzepatide achieved at least 15% weight loss, compared to 51% with semaglutide
For PT-141, the evidence is strongest: its FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in women, and it has meaningful off-label use in men for erectile and libido issues that dont respond to PDE5 inhibitors